Vardenafil (Levitra, Staxyn): Dosing, Effectiveness, Side Effects, and How It Compares to Other ED Drugs

What Is Vardenafil and How Does It Work?

Vardenafil blocks phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in penile smooth muscle. When sexual stimulation triggers nitric oxide release, cyclic GMP accumulates and relaxes corpus cavernosum smooth muscle, allowing arterial inflow and an erection. By inhibiting PDE5, vardenafil prolongs that cyclic GMP signal. The drug does not produce erections independently of arousal.

Bayer submitted vardenafil to the FDA under the trade name Levitra, and approval was granted in August 2003 [1]. The orally disintegrating 10 mg formulation (Staxyn) received separate FDA approval in June 2010 [2]. Generic vardenafil tablets became widely available in the United States after patent expiry, significantly reducing out-of-pocket costs.

Vardenafil's IC50 for PDE5 is approximately 0.7 nM, which is roughly 10 times more potent than sildenafil on a molar basis for the same enzyme. Critically, its selectivity ratio for PDE5 over PDE6 (the retinal phosphodiesterase responsible for colour-vision disturbances) is higher than sildenafil's, which explains the lower incidence of blue-tinge or photosensitivity reported by patients [3].

Dosing: How to Take Vardenafil Correctly

The standard starting dose is 10 mg taken approximately 25 to 60 minutes before sexual activity, no more than once every 24 hours. Clinicians may adjust up to 20 mg or down to 5 mg based on efficacy and tolerability. Men aged 65 and older typically start at 5 mg. Staxyn ODT is 10 mg only and dissolves on the tongue without water, which some patients find more convenient; it should never be substituted milligram-for-milligram with the tablet because the ODT produces approximately 21 to 28 percent higher systemic exposure than the conventional tablet at the same nominal dose [4].

High-fat meals are the single most important dietary interaction. A high-fat meal reduced vardenafil Cmax by approximately 18 to 50 percent and delayed Tmax by approximately one hour in pharmacokinetic studies cited in the Levitra prescribing information [4]. A low-fat meal has minimal impact. Taking vardenafil on an empty stomach or after a light snack optimises onset.

Dose adjustments required by specific conditions:

• Moderate hepatic impairment (Child-Pugh B): start at 5 mg, maximum 10 mg
• Severe hepatic impairment (Child-Pugh C): vardenafil is not recommended
• Alpha-blocker co-administration: initiate at 5 mg and titrate cautiously due to additive hypotension risk
• CYP3A4 inhibitors (ketoconazole 400 mg, ritonavir): maximum 2.5 mg per 72 hours due to dramatic AUC increases [4]

Effectiveness: What the Clinical Trial Data Show

Across the phase III program that supported FDA approval, vardenafil significantly improved erectile function scores versus placebo across multiple ED etiologies. In a key 12-week, double-blind trial (N=805) in men with mild-to-severe ED, vardenafil 10 mg and 20 mg produced International Index of Erectile Function (IIEF) erectile function domain scores of 22.5 and 23.9, respectively, compared with 13.4 for placebo (P<0.001) [5]. Sexual encounter diary data showed successful penetration in 65 to 80 percent of attempts on vardenafil versus 30 percent on placebo.

Men with diabetes mellitus, a population in whom ED medications often show reduced efficacy, responded to vardenafil in a dedicated 12-week trial (N=452). The percentage of successful intercourse attempts reached 57 percent on vardenafil 20 mg versus 28 percent on placebo [6].

A 2016 Cochrane systematic review of PDE5 inhibitors for erectile dysfunction (83 randomised controlled trials, N=12,234) confirmed that all four approved oral PDE5 inhibitors produced clinically meaningful improvements in IIEF scores relative to placebo, with no statistically significant differences in efficacy among agents when studies were pooled by drug class [7]. The clinical implication: individual patient response, tolerability, and dosing convenience should drive drug selection rather than assumed superiority of any single agent.

Side Effects and Safety Profile

Vardenafil's most common adverse effects are dose-dependent and stem from vasodilation. The Levitra prescribing information reports the following incidences at 10 to 20 mg doses versus placebo [4]:

• Headache: 15 percent vs. 4 percent
• Flushing: 11 percent vs. 1 percent
• Rhinitis (stuffy or runny nose): 9 percent vs. 3 percent
• Dyspepsia: 4 percent vs. 1 percent
• Sinusitis: 3 percent vs. 2 percent

Colour-vision disturbance (the blue-tinge effect mediated by PDE6 inhibition) occurred in fewer than 2 percent of men on vardenafil versus up to 11 percent reported for sildenafil in comparative pharmacological assessments [3]. Back pain and myalgia, more commonly associated with tadalafil, are not a prominent feature of vardenafil's profile.

Serious but rare adverse events include non-arteritic anterior ischemic optic neuropathy (NAION), sudden hearing loss, and priapism (erection lasting more than four hours). Patients who experience any of these should stop the drug and seek emergency care.

Absolute contraindications:

Nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, nitroprusside, amyl nitrite) are absolutely contraindicated with all PDE5 inhibitors. The combination produces severe, potentially fatal hypotension. The 2018 ACC/AHA guideline on stable ischemic heart disease states that PDE5 inhibitors must not be used within 24 hours of short-acting nitrates and within 48 hours of long-acting nitrates [8].

Soluble guanylate cyclase stimulators (riociguat) are also absolutely contraindicated due to additive hypotensive effects.

How Vardenafil Compares to Sildenafil (Viagra)

Sildenafil (Viagra), approved by the FDA in 1998, was the first oral PDE5 inhibitor. Both drugs share a similar mechanism, similar onset window (30 to 60 minutes), and similar four-to-six-hour duration. The pharmacological difference that matters most clinically is selectivity: vardenafil's lower affinity for PDE6 translates to fewer visual side effects. Sildenafil also inhibits PDE11 less than tadalafil but more than vardenafil does at equivalent therapeutic concentrations.

Food interaction is roughly comparable between the two: high-fat meals slow sildenafil absorption by a similar magnitude to vardenafil. Both are taken on-demand rather than daily. Neither agent has cardiovascular outcome data equivalent to tadalafil's CONFIRM program at this time.

Dosing comparison: sildenafil is available in 25 mg, 50 mg, and 100 mg tablets; the standard starting dose is 50 mg. Because potency per milligram differs (vardenafil's IC50 is approximately 10-fold lower), a 10 mg vardenafil dose is roughly pharmacodynamically equivalent to 50 mg sildenafil, though direct dose-equivalence tables are not validated in head-to-head trials.

Generic sildenafil is often less expensive than generic vardenafil at retail pharmacies, which matters for patients paying out of pocket. The 2023 GoodRx national average for sildenafil 50 mg (30 tablets) is approximately $25 to $40 with coupons, while generic vardenafil 10 mg (10 tablets) averages $60 to $90.

How Vardenafil Compares to Tadalafil (Cialis)

Tadalafil's defining clinical advantage is duration: its half-life of approximately 17.5 hours produces effects lasting up to 36 hours, enabling spontaneous sex without timing a dose around an encounter. Tadalafil is also available as a 2.5 mg or 5 mg once-daily formulation, which maintains steady plasma levels and removes the need for on-demand dosing altogether [9].

Vardenafil's four-to-five-hour window suits men who prefer shorter-duration coverage and want to reduce the number of hours of potential side effects. Tadalafil's longer half-life means that side effects, when they occur, also persist longer.

Tadalafil inhibits PDE11 more than vardenafil does. PDE11 is expressed in skeletal muscle and testicular tissue, which is why myalgia and back pain (reported in approximately 5 to 6 percent of tadalafil users) are more common with tadalafil than with vardenafil or sildenafil. Men with pre-existing musculoskeletal conditions may tolerate vardenafil better for this reason.

Tadalafil 5 mg daily also carries an FDA indication for benign prostatic hyperplasia (BPH) and can treat both ED and lower urinary tract symptoms with a single medication, a combination vardenafil cannot offer.

How Vardenafil Compares to Avanafil (Stendra)

Avanafil (Stendra) received FDA approval in 2012 and is marketed as the fastest-acting oral PDE5 inhibitor, with some men achieving erections sufficient for intercourse 15 minutes after a 200 mg dose in controlled trials [10]. Vardenafil's minimum recommended lead time is 25 minutes, though most clinical protocols specify 30 to 60 minutes.

Avanafil has a high selectivity ratio for PDE5 over PDE6 and PDE11, producing side-effect rates comparable to or slightly lower than vardenafil in head-to-head pharmacodynamic studies. The main practical disadvantage of avanafil is cost: generic avanafil is not yet widely available, and brand-name Stendra remains among the most expensive oral ED medications, often $30 to $50 per tablet without insurance.

For men who need the fastest possible on-demand option and can afford the cost, avanafil is a reasonable first choice. For men prioritising cost or seeking an orally disintegrating formulation, vardenafil (Staxyn ODT) offers a unique convenience advantage among generic-accessible options.

How Vardenafil Compares to Alprostadil (MUSE, Caverject, Edex)

Alprostadil acts through a completely different mechanism: it is a synthetic prostaglandin E1 (PGE1) that directly stimulates adenylyl cyclase in penile smooth muscle, raising cyclic AMP independent of nitric oxide or sexual arousal. Because it bypasses the nitric-oxide pathway, alprostadil can produce erections even in men with severe neurogenic or vascular ED who do not respond to any PDE5 inhibitor.

Three delivery forms exist:

1. Intraurethral pellet (MUSE, 125 to 1 to 000 mcg): inserted into the urethra with a small applicator; onset approximately 5 to 10 minutes
2. Intracavernosal injection (Caverject, Edex, generic alprostadil): injected directly into the corpus cavernosum; onset 5 to 20 minutes; doses typically 2.5 to 40 mcg
3. Topical cream (Vitaros in some countries; not FDA-approved in the United States)

The 2018 AUA guideline on erectile dysfunction positions PDE5 inhibitors, including vardenafil, as first-line pharmacotherapy. Intraurethral and intracavernosal alprostadil are second-line options for men who fail or cannot tolerate oral agents [11]. Alprostadil's main drawbacks include penile pain (reported in up to 33 percent of intracavernosal users), urethral burning (MUSE), and the inconvenience of self-injection or intraurethral administration. Priapism risk is also higher with intracavernosal alprostadil than with oral PDE5 inhibitors.

The practical decision point: a man who has tried two different PDE5 inhibitors at maximum tolerated doses with insufficient response should be evaluated for alprostadil before considering penile prosthesis implantation, per the AUA guideline algorithm [11].

Drug Interactions Beyond Nitrates

Beyond the absolute nitrate contraindication, vardenafil has several clinically significant interactions:

CYP3A4 inhibitors substantially raise vardenafil plasma levels. Ketoconazole 400 mg increases vardenafil AUC by 10-fold; ritonavir increases it by 49-fold. The Levitra label specifies a maximum of 2.5 mg per 72-hour period with ritonavir or other potent CYP3A4 inhibitors [4]. Grapefruit juice, a moderate CYP3A4 inhibitor, may also raise vardenafil levels modestly and is best avoided on dosing days.

Alpha-blockers (tamsulosin, doxazosin, terazosin) lower blood pressure and add to vardenafil's vasodilatory effect. Symptomatic orthostatic hypotension has been reported with this combination. The prescribing information recommends a minimum gap of six hours between a tamsulosin dose and vardenafil and advises starting vardenafil at 5 mg in alpha-blocker users [4].

Antiarrhythmics with QT-prolonging potential (quinidine, procainamide, amiodarone, sotalol) should be used with caution because vardenafil itself produces a small but measurable QT prolongation in pharmacodynamic studies. This interaction is listed as a contraindication in the Levitra label for Class IA and Class III antiarrhythmics [4].

Alcohol at moderate-to-high intake can compound vasodilatory hypotension and impair the psychogenic arousal needed for erection. Patients taking vardenafil should limit alcohol to no more than two standard drinks.

Who Is a Good Candidate for Vardenafil?

Vardenafil suits men who:

• Want an on-demand oral medication with a four-to-five-hour window (not the 24-to-36-hour coverage of tadalafil)
• Are bothered by the visual side effects (blue tinge, photosensitivity) they have experienced on sildenafil
• Prefer an orally disintegrating tablet (Staxyn) that dissolves without water
• Take moderate-dose alpha-blockers and need careful initial titration
• Cannot afford brand-name avanafil and want a fast-onset generic option

Vardenafil is less suitable for men who prefer spontaneous, unscheduled sex (tadalafil daily dosing fits better), men on potent CYP3A4 inhibitors such as ritonavir (dose adjustments are severe), or men with absolute contraindications to PDE5 inhibitors.

"The AUA Guideline recommends that clinicians discuss the benefits and risks of PDE5 inhibitors as first-line therapy with all men presenting with erectile dysfunction who have no contraindications," states the 2018 AUA ED guideline (Statement 18) [11]. This means vardenafil, as an approved PDE5 inhibitor with a well-established safety record since 2003, fits squarely within the standard of care for initial pharmacological management.

Starting Vardenafil: What to Expect at Your First Appointment

A clinician prescribing vardenafil for the first time should obtain a sexual and medical history, assess cardiovascular risk (since sexual activity and ED medications both have haemodynamic effects), and review the patient's full medication list for nitrate or CYP3A4 inhibitor use.

The Princeton Consensus III Panel (2012) stratified sexual activity risk into low, intermediate, and high cardiac risk categories. Men in the low-risk category (no symptoms on mild exertion, well-controlled hypertension, stable coronary artery disease) can start PDE5 inhibitors without additional cardiac evaluation. Men in the intermediate-risk category require stress testing before initiating treatment [12].

Laboratory work-up before prescribing ED medication should include fasting glucose or HbA1c (to screen for undiagnosed diabetes), total testosterone (low testosterone responds better to testosterone replacement than to PDE5 inhibitors alone), and lipid panel, per AUA guidance [11].

At the first attempt, patients should take vardenafil 10 mg approximately 45 minutes before anticipated sexual activity, after a light meal or on an empty stomach. If the first attempt is unsuccessful, patients should try the same dose on at least four to eight separate occasions before concluding that the drug is ineffective, because anxiety and learning effects influence early response rates. If 10 mg produces adequate erections but causes side effects, step down to 5 mg. If 10 mg is insufficient after eight attempts, step up to 20 mg with clinician oversight.